Abstract. Resistance to thyroid hormone (RTH) is caused mainly by mutations of the thyroid hormone receptor (TR) b gene. Although, in vitro, TRa1 and TRb1 mutants exhibit similar dominant negative effects against wild-type TR, no TRa mutants have ever been identified in RTH patients. It has been postulated that mutations in TRa gene may be lethal, compensated completely by intact TRb or associated with phenotypic manifestations different from RTH. To investigate the consequences of mutant TRa1 expression in vivo, we tried to generate two different lines of transgenic mice which express a strong or a weak dominant negative mutant TRa1, respectively. First, we expressed bF451X identified in a patient with severe RTH and aF397X, which has an identical C-terminal truncation and a similarly strong dominant negative potency to bF451X, under the control of human polypeptide chain elongation factor 1a promoter. Six bF451X-transgenic mice were born from 223 transferred embryos, giving a transgenic frequency of 2.7%. By contrast, expression of aF397X resulted in quite a low transgenic frequency with 0.39% of the transferred embryos bearing the transgene. Only three transgenic mice were born with no apparently overt abnormalities, of which one male produced F1 offspring. The transgenic progeny expressed aF397X in the testis but we did not succeed in generating transgenic mice expressing aF397X in multiple organs. To avoid toxic effects mediated by a strong dominant negative activity of mutant TRa1, we exchanged aF397X for aK389E, which has an identical missense mutation and a relatively weak transdominant potency as bK443E identified in a patient with mild RTH. When expressed by cytomegalovirus immediate early enhancer-chicken b-actin promoter, we did not succeed in creating aK389E-transgenic mice despite three independent transgene-injections. These findings define crucial in vivo functions of mutant TRa1s during mouse fetal development and suggest the possibility that the expression of a dominant negative mutant TRa1 in extensive tissues from the early embryonal stages might be lethal.
THYROID hormone (T3) exerts a profound effect on many functions in development and homeostasis. Its role is mediated by nuclear thyroid hormone receptors (TRs) encoded by two distinct genes, TRa and TRb. In mammals, each gene gives rise to two major isoforms, TRa1 and a2, and TRb1 and b2, by alternative splicing of the primary transcripts. In vitro, TRa1 and TRb can transactivate through the same T3 responsive elements (TREs), suggesting that they have the potential to regulate common functions. However, ontogenetic and functional differences among TR isoforms have been demonstrated. The TRa gene is widely and constantly expressed from the early developmental stages, whereas the expression of the TRb gene is highly restricted and starts later in embryogenesis followed by a sharp increase with neonatal development [1, 2] . TRb plays an essential role in TSH regulation and cochlear development [3, 4] , while TRa is more important in mediating adrenergic signaling in heart functions [5, 6] .
Resistance to thyroid hormone (RTH) is a hereditary human disease characterized by normal or elevated levels of thyrotropin (TSH) in the presence of high levels of serum thyroid hormone (syndrome of inappropriate secretion of TSH: SITSH) and resistance of central and peripheral tissues to the actions of thyroid hormone [7] . RTH is linked to both deletion and point mutations of the human TRb gene. The RTH patient with a deletion of the two human TRb alleles exhibits SITSH, hearing loss and a bone developmental abnormality [8] . Knocking out all TRb isoforms recapitulates SITSH and loss of auditory function in mice [9] . RTH patients with a transdominant negative mutant TRb often suffer from goiter, attention deficit hyperactivity disorder, lower intelligence, speech impediment, hearing loss and short stature [7, 10] . Mice with a mutation knocked in one of the two TRb alleles exhibit resistance to thyroid hormone and manifest impaired weight gain and delayed bone development [11] .
In contrast, no deletion mutants of the TRa gene have ever been identified in RTH patients. Knock-out mice which lack functional TRa1 exhibit mild hypothyroxinemia, bradycardia and lower body temperature but not SITSH [6] . Another knock-out mouse model with homozygous inactivation of both TRa1 and a2 demonstrates hypothyroidic features and exhibits growth arrest with strongly delayed maturation of small intestine and bones [12] . These findings suggest the possibility that deletion of the TRa gene may not be associated with the abnormalities observed in RTH. Furthermore, a dominant negative mutation knocked in one of the two TRa1 gene causes increased mortality, reduced fertility, dwarfism and mild thyroid failure in mice [13] . The distinct phenotypes of mice with an identical mutation at TRb1 and TRa1 locus indicate the in vivo functions of TR mutants are TR subtype-dependent [11, 13] .
It is unclear why no TRa mutations have ever been found in RTH patients. It has been postulated that dominant negative germinal mutations in the TRa gene could result in a more severe phenotype, such as an intrauterine lethal condition with no childbirth. Although mice with a targeted mutation in one of the two TRa1 alleles were successfully generated [13, 14] , the expression of the mutant allele was not compared with that of the wild-type TRa1 allele on protein level. It may be possible that only the mutant mice with a lesser expression of a mutant TRa1 were born and survived.
Reduced expression of a mutant gene might result in mild phenotypes in vivo. We therefore tried to generate transgenic mice which abundantly and widely express a dominant negative mutant human TRa1 by using strong heterologous promoters. Our results showed that the expression of a dominant negative mutant TRa1 from the early embryonal stages leads to embryonic lethality of the transgenic mice, which suggested the deleterious effects of mutant TRa1s on intrauterine fetal development in mice.
Materials and Methods
Construction of EF1a-bF451X, EF1a-aF397X and CAG-FLAGaK389E transgenes
We expressed bF451X and aF397X under the control of human polypeptide chain elongation factor 1a promoter (EF1a-promoter). The EF1a-bF451X and EF1a-aF397X transgenes were constructed as follows. A 1.5 kbp HindIII/BamHI fragment containing bF451X cDNA and a 1.9 kbp HindIII/BamHI fragment containing aF397X cDNA were derived from pCMX-bF451X and pCMX-aF397X, respectively [15] . Both fragments were filled in using the Klenow enzyme and inserted into the blunt-ended XbaI site of pEF-BOS, which was kindly provided by Dr. S. Nagata [16] . Two transgenes, which contain the EF1a-promoter, the coding sequence of either bF-451X or aF397X and the human G-CSF polyadenylation signal, were released from the recombinant pEFBOSs by digestion with HindIII and ScaI and designated as EF1a-bF451X (3.2 kbp) and EF1a-aF397X (3.6 kbp), respectively. The other mutant TRa1, aK389E, was expressed under the direction of a composite promoter consisting of cytomegalovirus immediate early enhancer and chicken b-actin promoter (CAG-promoter). The CAG-FLAGaK389E transgene was constructed by the following steps. An aK389E mutation equivalent to that in bK443E was made by substituting triplet AAA for GAA at position 389 in the human TRa1 coding region as follows. Polymerase chain reaction (PCR) was performed with the sense primer 5'-AGGCTGTGCTGCTAATGTCAA-3', which has a BspMI recognition site, and the antisense primer 5'-AAAGACCTCGAGGAAGAGTGGGGGG AAGAGTTCGGTGGGGCACTCGACTTCCATG-3', which has base substitutions to introduce a glutamic acid codon at position 389 and has a downstream XhoI recognition sequence. After digesting the PCR product with BspMI and XhoI, the resulting 161 bp DNA fragment was substituted for the identical portion of wild-type human TRa1 cDNA in pCMX-FLAGTRa1 [17] and designated as pCMX-FLAGaK389E. A 1.9 kbp EcoRI/EcoRI fragment containing FLAGaK389E cDNA was excised from pCMX-FLAGaK389E. The fragment was inserted into the EcoRI site of pCAGGS, which was a generous gift from Dr. J. Miyazaki [18] . A 3.5 kbp fragment containing the CAG-promoter, the FLAGaK389E cDNA sequence and the rabbit bglobin polyadenylation signal was released by digestion with SalI and HindIII and designated as CAGFLAGaK389E.
Production of transgenic mice
The experimental protocol and design were approved by the Animal Experimentation Committee of Hamamatsu University School of Medicine and performed according to the Guidelines for Animal Experimentation. EF1a-bF451X, EF1a-aF397X and CAGFLAGaK389E transgenes were isolated by extraction from agarose gel after size-separation electrophoresis. The fragments were further purified twice using a GeneClean II kit (Bio101, Inc., Vista, CA, USA) and reconstituted at 5 ng/mL in TE (10 mM Tris-HCl, pH 7.4, and 1 mM EDTA) for EF1a-bF451X and EF1a-aF397X and 0.5 x TE for CAG-FLAGaK389E. The purified transgenes were microinjected into the pronuclei of one-cell stage eggs from C57BL/6JxDBA2F1 for EF1a-transgenes and C57 BL/6Crslc for CAGFLAGaK389E according to Hogan and Lacy [19] . Twenty-four hours later the embryos were implanted into the oviducts of pseudopregnant C57BL/6 mice. Litters were delivered after approximately 20 days gestation. Transgenic mice carrying EF1a-transgenes were generated at the transgenic facilities of Takeda Chemical Industries, Ltd. Transgenic mice carrying CAG-FLAGaK389E were generated at the transgenic facilities of Japan SLC Co.
Identification of transgenic mice
The incorporation of the transgene in founder mice was screened by PCR of genomic DNA. Genomic DNA was prepared from mouse tails using an Easy DNA kit (Invitrogen, Groningen, Netherlands) or by lysis for 48 h at 55ºC in 700 mL of 50 mM Tris-HCl (pH 7.5), 100 mM EDTA, 0.5% SDS and 250 mg/mL Proteinase K. The primers for screening were as follows.
The sense primer P1 and the antisense primer P2 correspond to sequences of exon 9 and exon 10 of human TRb1 cDNA, respectively. The pair of P1 and P2 primers produces a 275 bp fragment of human TRb1 cDNA. The sense primers P3 and P5 correspond to the sequences of exon 8 and exon 5 of human TRa1 cDNA, respectively. The sense primer P7 is complementary to an antigenic FLAG peptide coding sequence. The antisense primers P4, P6 and P8 correspond to the sequences of exon 9, exon 8 and exon 4 of human TRa1 cDNA, respectively. The pair of P3 and P4 primers and the pair of P5 and P6 primers lead to a 244 bp fragment and a 588 bp fragment of human TRa1 cDNA, respectively. The pair of P7 and P8 primers yields a 300 bp fragment specific for FLAGtagged mutant human TRa1 cDNA. The PCR reactions were carried out using 500 ng genomic DNA, 1 pmol/mL primers, 0.2 mM dNTPs and 0.025 U/mL Takara ExTaq DNA polymerase (Takara Shuzo Co., Ltd., Otsu, Japan) in 25-100 mL of PCR buffer consisting of 10 mM Tris-HCl (pH 9.0), 50 mM KCl and 1.5 mM MgCl2.
The presence of EF1a-bF451X, EF1a-aF397X and CAG-FLAGaK389E in the founder mice was ascertained by Southern blot analysis. The DNA samples were digested with EcoRI endonuclease, resolved on an agarose gel, and transferred onto a nylon membrane. The DNAs were hybridized with a 32 P-labeled 270 bp SmaI/BamHI fragment of human TRb1 cDNA for EF1a-bF451X, a 32 P-labeled 350 bp PstI/BamHI fragment of human TRa1 cDNA for EF1a-aF397X and a 32 P-labeled 626 bp XhoI/BamHI fragment of FLAGaK389E cDNA for CAG-FLAGaK389E, respectively. If the transgenes were inserted into the mouse genome, EcoRI digestion would generate a 2.2 kbp fragment of EF1a-bF451X and a 2.6 kbp fragment of EF1a-aF397X and a 1.9 kbp fragment of CAG-FLAGaK389E, respectively.
Detection of transgene expression
Total RNA was extracted according to the manufacturer's instructions using TRIzol reagent (Life Technologies Inc., Rockville, MD, USA) and a Qiagen RNeasy Protect Mini kit (Qiagen, Hilden, Germany). After treatment of RNA with RNase-free DNase I, tissue specific expression of the transgene was determined by RT-PCR. For RNA from mice bearing EF1a-aF397X, the first cDNA was synthesized by reverse transcription using oligo dT primer. In the next step, a 24 bp sense oligo 5'-AAGCTGCTGATGAAG GTGACTGAC-3' and a 24 bp antisense oligo 5'-AAA GACCTCGAGGAAGAGTGGGAG-3' were used to amplify a 120 bp fragment of the human TRa1 cDNA, which, when digested with HinfI, yielded two fragments of 96 bp and 24 bp from human but not mouse TRa1 mRNA. To exclude the possibility of mouse genomic DNA contamination, amplification of the mutant human TRa1 transcripts was performed after including a mock reverse transcription-sample by omitting the reverse transcriptase in the cDNA synthesis reaction. The mock reverse transcription samples did not yield any cDNA fragments.
Analysis of transgenic fetuses bearing the CAGFLAGaK389E transgene
Two hundred and eighty CAG-FLAGaK389E-injected eggs were transferred into pseudopregnant females. The foster mothers were euthanized on embryo day 18 (E18) and intrauterine fetuses were harvested by cesarean section. The acquired fetuses were divided into four groups with regard to intrauterine development. The fetuses in the first group died during the earlier developmental stages (before E8) before placental formation. The fetuses in the second group died during the mid developmental stages (E8 to E14) after placental formation but before completion of limb development. In the third group, we saw fully separated forelimbs and hindlimbs in the fetuses, which died during the later developmental stages (beyond E14). The fourth group was live fetuses at E18. The presence of the transgene was ascertained by PCR of the embryoblast, yolk sac or tail genomic DNA of mouse embryos and fetuses as described above. Fetuses that died during the mid and the late developmental stages and live fetuses were dissected and compared between transgenic and non-transgenic with respect to the abnormality of internal organs. The expression of FLAGaK389E was examined in the dissected major organs, such as heart, lung, liver, kidney and so on, by Western blot analysis using a primary anti-FLAG antibody as described previously [17] .
Results
Production of transgenic mice harboring the EF1a-bF451X and the EF1a-aF397X transgene
We chose bF451X and aF397X as exogenously expressed mutant TRs in transgenic mice. aF397X has the equivalent C-terminal truncation to bF451X identified in a patient with severe RTH [20] . In a transient transfection assay in CV-1 cells, aF397X showed strong dominant negative effects comparable to bF451X through several positive TREs [15] . We carried out microinjection of the transgene into fertilized eggs once for the EF1a-bF451X and eight times for the EF1a-aF397X. The numbers of transferred embryos and born mice are shown in Table 1 . Two hundred and twenty-three bF451X-injected eggs were transferred into foster mothers and six transgenic mice were born as determined by Southern blot analysis (Fig. 1A) , giving a transgenic frequency of 2.7% (6/223). By contrast, a total of 764 aF397X-injected eggs were transferred, resulting in a total of 3 transgenic mice as determined by Southern blot analysis (Fig. 1B) , giving a transgenic frequency of 0.39% (3/764). The transgenic frequency for aF397X-transgenic mice was approximately one-seventh of that of bF451X-transgenic mice. One of the three aF397X-transgenic mice died soon after birth and we finally obtained only two adult male aF397X-transgenic mice (male 1 and male 2). Although no abnormalities were observed in body structure or suckling and feeding behaviors, the two transgenic mice were relatively underweight from 4 months to 11 months of age (Fig. 2) .
Only transgenic mouse-male 1 produced F1 offspring by mating with C57BL/6 females.
Analysis of the expression of aF397X in transgenic mice
Since tissues of the dead F0 transgenic mouse failed to be preserved and tissue samples of the two founder mice were fixed in formaldehyde solution for morphological and immunohistochemical examinations, we did not extract RNA from the F0 transgenic mice. To evaluate the expression level and pattern of aF397X in transgenic mice, total RNA was isolated from various tissues of the transgenic and non-transgenic F1 offspring from male 1. The F1 transgenic mice did not exhibit obvious phenotypes and, at autopsy, gross examination revealed no overt abnormalities in the major organs. RT-PCR was used to amplify a 120 bp cDNA fragment, which is common for aF397X cDNA and mouse endogenous TRa gene. The expression of aF397X was assessed by treating the 120 bp fragment with the restriction enzyme HinfI. Fig. 3 shows a representative result of F1 transgenic mice from male 1. Only the RNA from the testis of the transgenic mice shows the expected 96 bp fragment in 8% PAGE (Fig. 3, lane 2) . This expression was specific because no such fragment was seen in the RNA isolated from the testis of the non-transgenic mice (Fig. 3, lane 1) . Lanes 3-9 show no detectable expression of aF397X in the ovary, pituitary, thyroid, brain, heart, kidney and liver of transgenic mice, respectively.
Production of transgenic mice harboring the CAGFLAGaK389E transgene
The very low transgenic frequency of the EF1a-aF397X transgenic mice might be due to the very strong dominant negative potency of aF397X. We then tried to create transgenic mice using a milder dominant negative mutant TRa1, aK389E, and a different heterologous transgene promoter, the CAGpromoter. aK389E has the identical missense mutation at the 389th amino acid to bK443E identified in a patient who shows moderate resistance to thyroid hormone [21] . In the CV-1 cells, transiently expressed aK389E exhibited weak dominant negative effects equivalent to bK443E through several positive TREs (unpublished data). To detect aK389E easily, an oligonucleotide encoding an antigenic FLAG peptide was inserted in front of aK389E cDNA. We carried out three separate microinjections of the CAGFLAGaK389E transgene. The numbers of transferred embryos and born mice are shown in Table 2 .
Throughout the experiments, only 4 out of 105 born pups demonstrated a 300 bp specific for FLAG-tagged mutant TRa1 cDNA by a PCR analysis using P7 and P8 primers (Fig. 4, lanes 3-6) . However, Southern blot analysis did not detect the transgene with the expected size of 1.9 kbp, while transgenic and non-transgenic mice showed a 5.0 kbp band derived from mouse TRa gene (Fig. 5, lanes 1-5) . These results indicate that a fragment of the transgene was incorporated into mouse genomic DNA, but no transgenic mice were born which carried the entire CAG-FLAGaK389E transgene. Nuclear lysates prepared from tissue samples of the PCR-positive mice were size fractionated on a 10% SDS-PAGE gel and Western blot analysis was carried out using a primary anti-FLAG monoclonal antibody as described previously [17] . However, the analysis did not detect FLAG-fused TR bands (data not shown).
Analysis of transgenic fetuses bearing the CAGFLAGaK389E transgene
The difficulty in obtaining the transgenic mice expressing a mutant TRa1 raises the possibility that abundant expression of a dominant negative mutant TRa1 from early embryonal stages could be deleterious to intrauterine embryonic development in the mouse. We thus collected dead and live mouse fetuses on the 18th day of gestation and analyzed prenatal development of FLAGaK389E transgenic fetuses. The numbers of transgenic and non-transgenic fetuses at four separate intrauterine developmental stages are shown in Table 3 . A marked increase in mortality was not observed in transgenic fetuses of any embryonic stages. Macroscopic anatomy revealed no overt abnormalities either in the dead or the survived transgenic fetuses when compared with non-transgenic fetuses that died during the same periods and nontransgenic live fetuses, respectively. The expression of FLAGaK389E was also examined in the dissected major organs by Western blot analysis using a primary anti-FLAG antibody, but we did not detect aK389E expression in any organs of the transgene-incorporated fetuses (data not shown). Immature embryos and fetuses before placental formation were too small to analyze the expression of the transgene.
Discussion
Human TRa1 is expressed ubiquitously from the early embryonic stages on and plays important roles in normal embryonic development. The present experiments were designed to examine the consequences of abundant expression of a dominant negative mutant human TRa1 in developing mouse embryos and postnatal development of the mouse. We tried to generate two kinds of transgenic mice, EF1a-aF397X and CAG-FLAGaK389E, which harbor mutant TRa1 cDNAs driven by ubiquitously strong promoters. We chose EF1a-and CAG-promoters because both promoters produce high-level expression of various ligated genes from the early embryonal stages in almost all tissues in transgenic mice [18, [22] [23] [24] [25] [26] .
We expected aF397X-transgenic mice to have expressed aF397X in widespread organs. However, our results showed that the transgenic frequency of the EF1a-aF397X-transgenic mice was very low and the expression of the mutant restricted to the testis. These findings suggest the possibility that the expected transgenic embryos expressing aF397X in various organs are unable to survive during fetal period, and that only the embryos expressing aF397X in restricted organs, such as the testis, could live to birth and thrive. It is also possible that we may have happened to obtain a strain of the aF397X-transgenic mice which has an unusual expression pattern of the transgene.
In the case of CAG-FLAGaK389E, we did not succeed in generating any transgenic mice expressing aK389E despite its weak dominant negative potency. In a comparison of transgene expression mediated by various heterologous promoters, the CAG-promoter has been reported to have a stronger promoter activity than the EF1a-promoter as a Cre expression vector in embryonic stem cells [27] . Thus, it is possible that aK389E-transgenic mice could not survive when aK389E was expressed more abundantly in widespread organs by the stronger CAG-promoter, even though aK389E exerts milder dominant negative effects than aF397X.
Our results suggest that abundant mutant TRa1 expression driven by the EF1a-and CAG-promoters must be toxic or lethal to mouse embryonic development, making it difficult for mice widely expressing the dominant negative mutant TRa1 to survive until birth. From the analysis of intrauterine transgenic fetuses harboring CAG-FLAGaK389E, it is speculated that transgenic fetuses widely and abundantly expressing a mutant TRa1 are at high risk of dying during the very early embryonal periods, and that transgenic fetuses that survived beyond mid embryonal stages either do not express the dominant negative mutant TRa1 or do so in extremely minute amounts.
Resistance to thyroid hormone (RTH) is a genetic disease mainly caused by mutations of the TRb gene. Mutant human TRb1s have been expressed in several transgenic mice, which exhibited phenotypic features consistent with the clinical features of RTH. The transgenic mice expressing bT448fs in extensive tissues under the control of human b-actin promoter are viable and display elevated thyroid hormone levels, decreased body weight and hyperactivity [28] . In other transgenic mice, the expression of bT337D in extensive tissues using the CAG-promoter exerts a Two hundred and eighty injected eggs were transferred into foster mothers.
strong dominant negative effect in the hearts of transgenic mice, leading to a hypothyroid cardiac phenotype [29] . Although the mortality rate of the bT337D-transgenic fetuses and the expression pattern of the transgene in the tissues other than the heart were not reported, the transgenic mice survived to birth when they expressed a strong dominant negative mutant TRb1, bT337D, under the control of the same CAGpromoter as we used. Different from the expression of mutant TRb1s in mice, our present study suggests that the expression of a dominant negative mutant TRa1 leads to an increased mortality rate during prenatal development. We assume that a dominant negative mutant TRa1 exerts a distinct effect from RTH-mutant TRb1s on the intrauterine embryonal development. The increased mortality rate of fetuses could cause a rare transmission of a dominant negative mutant TRa1 to posterity through germinal cells, and that may be one of the reasons for the difficulties in uncovering familial disorders caused by a mutation of human TRa-gene.
